In an article from the Boston Globe, it is disclosed that three marketing firms developed marketing programs to promote Neurontin (an adjunct epilepsy drug) for uses not approved by the FDA there by allowing the drug maker to make more profit while attempting to stay out of trouble.
Neurontin marketing plan disclosed
Court documents show that drug giant Parke-Davis hired three outside medical advertising and education firms to develop strategies for promoting its epilepsy drug Neurontin for unapproved uses, tactics that included continuing medical education classes for physicians, “home study kits” for doctors who couldn’t attend meetings, prepaid calling cards that would trigger recorded messages about Neurontin, Web sites, and special supplements to medical journals.
Stories like this just destroy any possible trust relationship between marketer/company and the consumer.
